United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (megaesophagus) and myasthenia gravis. contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.

Israel - English - Ministry of Health

teva israel ltd - orphenadrine (citrate); paracetamol - tablets - paracetamol 500 mg; orphenadrine (citrate) 30 mg - orphenadrine, combinations - orphenadrine, combinations - relief of mild to moderate pain of acute musculoskeletal disorders.

Canada - English - Health Canada

sterimax inc - orphenadrine citrate - liquid - 30mg - orphenadrine citrate 30mg - miscellaneous skeletal muscle relaxants

United States - English - NLM (National Library of Medicine)

galt pharmaceuticals, llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - orphengesic forte (orphenadrine citrate, aspirin and caffeine 50 mg/ 770 mg/ 60 mg) tablets are indicated in: - symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. - the orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. orphengesic forte tablets do not directly relax tense muscles in man. because of the mild anticholinergic effect of orphenadrine, orphengesic forte tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy or obstructions at the bladder neck. orphengesic forte tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. the drug is contraindicated in patients who have demonstrated a previous h

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk; sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

Kenya - English - Pharmacy and Poisons Board

orphenadrine citrate paracetamol - tablet - orphenadrine citrate 35 mg/tablet paracetamol 450… - orphenadrine combinations

United States - English - NLM (National Library of Medicine)

galt pharmaceuticals, llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - orphengesic forte (orphenadrine citrate, aspirin and caffeine 50 mg/ 770 mg/ 60 mg) tablets are indicated in: - symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. - the orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. orphengesic forte tablets do not directly relax tense muscles in man. because of the mild anticholinergic effect of orphenadrine, orphengesic forte tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy or obstructions at the bladder neck. orphengesic forte tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. the drug is contraindicated in patients who have demonstrated a previous h

United States - English - NLM (National Library of Medicine)

galt pharmaceuticals, llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - norgesic tm (orphenadrine citrate, aspirin and caffeine 25 mg/ 385 mg/ 30 mg) tablets are indicated in: - symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. - the orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. norgesic tm tablets do not directly relax tense muscles in man. because of the mild anticholinergic effect of orphenadrine, norgesic tm tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy or obstructions at the bladder neck. norgesic tm tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. the drug is contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.